Comparison of the Efficacy and Safety of Rivaroxaban and Low Molecular Heparin in Preventing Venous Thromboembolism in Inpatient Cancer Patients.

Shuyi WuChengfu GuanSijie ChangChunhua WangJin-Hua Zhang

Published in: The Annals of pharmacotherapy (2023)

In thromboprophylaxis in inpatient cancer patients, rivaroxaban has a similar rate of VTE and bleeding events as LMWH. Our results may provide a reference for the clinical use of rivaroxaban to prevent VTE in hospitalized cancer patients.

Keyphrases

venous thromboembolism
direct oral anticoagulants
palliative care
mental health
atrial fibrillation
acute care
pulmonary embolism